secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-262576
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q3 net loss widens to $55.8M; first IBTROZI revenue $7.7M
----------------------------------------------------------------------

- Net loss $55.8M ($0.16 loss per share) vs. $41.2M ($0.15) in Q3 2024.
- Net product revenue from IBTROZI $7.7M; collaboration revenue $5.4M (up from $0.7M).
- 204 new patients started IBTROZI in Q3; median duration of response matured to 50 months.
- Cash, cash equivalents, and marketable securities $549.0M at Sept 30, 2025.
- First patients enrolled in TRUST-IV adjuvant study and safusidenib G203 study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525262576/0001193125-25-262576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525262576/d21938d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-262576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer